Patents by Inventor Akira Shimotoyodome
Akira Shimotoyodome has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10494430Abstract: Provide is an anti-active GIP antibody which allows accurate detection of active GIP. The present invention provides an anti-active GIP antibody which binds to active GIP and does not substantially bind to nonactive GIP, the antibody recognizing at least one or more amino acids selected from the group consisting of amino acids at 8th to 10th position of the amino acid sequence represented by SEQ ID NO: 5, and comprising, in an H chain, a region comprising the following amino acid sequence (1) or a conservative sequence modification thereof: EMNPSDGRTHFNE (1).Type: GrantFiled: December 21, 2015Date of Patent: December 3, 2019Assignee: Kao CorporationInventors: Daisuke Fukuoka, Noriko Osaki, Akira Shimotoyodome
-
Publication number: 20170369569Abstract: Provide is an anti-active GIP antibody which allows accurate detection of active GIP. The present invention provides an anti-active GIP antibody which binds to active GIP and does not substantially bind to nonactive GIP, the antibody recognizing at least one or more amino acids selected from the group consisting of amino acids at 8th to 10th position of the amino acid sequence represented by SEQ ID NO: 5, and comprising, in an H chain, a region comprising the following amino acid sequence (1) or a conservative sequence modification thereof: EMNPSDGRTHFNE (1).Type: ApplicationFiled: December 21, 2015Publication date: December 28, 2017Applicant: Kao CorporationInventors: Daisuke FUKUOKA, Noriko OSAKI, Akira SHIMOTOYODOME
-
Patent number: 8933025Abstract: An agent for suppressing postprandial elevation of blood insulin concentration, comprising a polyglutamic acid as an active ingredient.Type: GrantFiled: July 16, 2010Date of Patent: January 13, 2015Assignee: Kao CorporationInventors: Kotomi Ishimaru, Kazuhisa Sawada, Akira Shimotoyodome
-
Patent number: 8853153Abstract: An agent for suppressing elevation of blood GIP concentration and an agent for preventing or improving obesity, each of which contains a polyglutamic acid as an active ingredient.Type: GrantFiled: July 16, 2010Date of Patent: October 7, 2014Assignee: Kao CorporationInventors: Kotomi Ishimaru, Kazuhisa Sawada, Akira Shimotoyodome
-
Patent number: 8828935Abstract: An agent for suppressing elevation of a blood triglyceride concentration, comprising a polyglutamic acid as an active ingredient.Type: GrantFiled: July 16, 2010Date of Patent: September 9, 2014Assignee: KAO CorporationInventors: Kotomi Ishimaru, Kazuhisa Sawada, Akira Shimotoyodome
-
Patent number: 8501721Abstract: A postprandial hyperglycemia-improving agent, the agent is highly safe and exhibits excellent effects of inhibiting the postprandial increase of blood glucose. The postprandial hyperglycemia-improving agent comprises a cycloartenol or a derivative thereof as an active ingredient.Type: GrantFiled: January 15, 2010Date of Patent: August 6, 2013Assignee: Kao CorporationInventors: Daisuke Fukuoka, Kohjiro Hashizume, Akira Shimotoyodome
-
Patent number: 8338389Abstract: The present invention provides a method for preventing or ameliorating obesity, for inhibiting accumulation of visceral fat, for inhibiting accumulation of liver lipid, for preventing or ameliorating fatty liver, including using a material for a pharmaceutical product or food, which has inhibitory actions on body weight increase, accumulation of visceral fat and accumulation of liver lipid. The present invention is also directed to a method for preventing or ameliorating obesity, a method for inhibiting accumulation of visceral fat, a method for inhibiting accumulation of liver lipid, and a method for preventing or ameliorating fatty liver, which methods include administering potassium alginate to a subject in need thereof or having the subject take potassium alginate.Type: GrantFiled: June 17, 2010Date of Patent: December 25, 2012Assignee: Kao CorporationInventors: Junko Suzuki, Akira Shimotoyodome, Tomohisa Ichiba
-
Patent number: 8283338Abstract: The present invention provides a postprandial GIP secretion inhibitor comprising potassium alginate as an active ingredient. The postprandial GIP secretion inhibitor of the present invention is useful as a medicine or a food product. The present invention also provides use of potassium alginate for the manufacture of a postprandial GIP secretion inhibitor. The present invention also provides a method for inhibiting postprandial GIP secretion, which comprises administering potassium alginate to a subject in need thereof or causing a subject in need thereof to consume potassium alginate.Type: GrantFiled: November 28, 2008Date of Patent: October 9, 2012Assignee: Kao CorporationInventors: Junko Suzuki, Akira Shimotoyodome, Tomohisa Ichiba
-
Publication number: 20120122772Abstract: An agent for suppressing elevation of blood GIP concentration and an agent for preventing or improving obesity, each of which contains a polyglutamic acid as an active ingredient.Type: ApplicationFiled: July 16, 2010Publication date: May 17, 2012Applicant: Kao CorporationInventors: Kotomi Ishimaru, Kazuhisa Sawada, Akira Shimotoyodome
-
Publication number: 20120115779Abstract: An agent for suppressing elevation of a blood triglyceride concentration, comprising a polyglutamic acid as an active ingredient.Type: ApplicationFiled: July 16, 2010Publication date: May 10, 2012Applicant: Kao CorporationInventors: Kotomi Ishimaru, Kazuhisa Sawada, Akira Shimotoyodome
-
Patent number: 8071572Abstract: The present invention relates to a preventive/remedy for obesity, which has a hydroxypropylated starch as its active ingredient. Provided are materials for foods, drugs, etc. which can exhibit an effect of preventing/lessening the onset of various lifestyle related diseases, for example, an effect of preventing/ameliorating obesity, or preventing/ameliorating hyperlipidemia; have a high safety and a wide application range; and rarely damage their texture.Type: GrantFiled: March 8, 2004Date of Patent: December 6, 2011Assignee: Kao CorporationInventors: Akira Shimotoyodome, Junko Suzuki, Noriyuki Yajima, Takatoshi Murase, Ichirou Tokimitsu
-
Publication number: 20110275605Abstract: A postprandial hyperglycemia-improving agent, the agent is highly safe and exhibits excellent effects of inhibiting the postprandial increase of blood glucose. The postprandial hyperglycemia-improving agent comprises a cycloartenol or a derivative thereof as an active ingredient.Type: ApplicationFiled: January 15, 2010Publication date: November 10, 2011Inventors: Daisuke Fukuoka, Kohjiro Hashizume, Akira Shimotoyodome
-
Publication number: 20110268826Abstract: A GIP-increase inhibitor, which is useful as a drug or a food, comprising a rice bran extract as an active ingredient.Type: ApplicationFiled: January 15, 2010Publication date: November 3, 2011Applicant: Kao CorporationInventors: Daisuke Fukuoka, Kohjiro Hashizume, Akira Shimotoyodome
-
Publication number: 20110098245Abstract: The present invention provides a method for preventing or ameliorating obesity, for inhibiting accumulation of visceral fat, for inhibiting accumulation of liver lipid, for preventing or ameliorating fatty liver, including using a material for a pharmaceutical product or food, which has inhibitory actions on body weight increase, accumulation of visceral fat and accumulation of liver lipid. The present invention is also directed to a method for preventing or ameliorating obesity, a method for inhibiting accumulation of visceral fat, a method for inhibiting accumulation of liver lipid, and a method for preventing or ameliorating fatty liver, which methods include administering potassium alginate to a subject in need thereof or having the subject take potassium alginate.Type: ApplicationFiled: June 17, 2010Publication date: April 28, 2011Applicant: KAO CORPORATIONInventors: Junko SUZUKI, Akira SHIMOTOYODOME, Tomohisa ICHIBA
-
Publication number: 20100209550Abstract: The present invention relates to pet foods containing carbohydrates that include high-amylose starch, and an animal or vegetable protein. They are excellent in benefits such as having an anti-obesity effect and do not impair the pet's appetite or food intake.Type: ApplicationFiled: April 29, 2010Publication date: August 19, 2010Applicant: KAO CORPORATIONInventors: Tomoshige UMEDA, Akira Ooshima, Junko Suzuki, Akira Shimotoyodome
-
Publication number: 20100022014Abstract: A method for efficiently evaluating or selecting an obesity controlling substance, a blood insulin regulating substance or a blood sugar regulating substance, is provided. A method for evaluating or screening an obesity controller, the method including administering a carbohydrate and a lipid to an animal, and evaluating or selecting a substance which decreases or increases insulin secretion, is also provided.Type: ApplicationFiled: November 7, 2007Publication date: January 28, 2010Applicant: Kao CorporationInventors: Akira Shimotoyodome, Junko Suzuki, Nanami Takeno, Daisuke Fukuoka, Tomohito Mizuno, Shinichi Meguro
-
Publication number: 20090202704Abstract: The present invention provides a postprandial hyperglycemia-improving agent, which is useful as a food or a pharmaceutical product. The postprandial hyperglycemia-improving agent includes, as an active ingredient, a fat and oil composition containing 5% by mass or more of a diglyceride and/or a monoglyceride in which an ?9 unsaturated fatty acid content in constituent fatty acids is 35% by mass or more.Type: ApplicationFiled: February 11, 2009Publication date: August 13, 2009Applicant: Kao CorporationInventors: Noriko Osaki, Koji Onizawa, Akira Shimotoyodome
-
Publication number: 20090192223Abstract: The object of the invention is to provide a GIP secretion inhibitor which is a useful drug or food ingredient. The present invention provides an agent for inhibiting postprandial GIP secretion contains a monoacylglycerol as an active ingredient.Type: ApplicationFiled: April 4, 2007Publication date: July 30, 2009Applicant: KAO CorporationInventors: Nanami Takeno, Akira Shimotoyodome, Shinichi Meguro
-
Publication number: 20090143329Abstract: The present invention provides a postprandial GIP secretion inhibitor comprising potassium alginate as an active ingredient. The postprandial GIP secretion inhibitor of the present invention is useful as a medicine or a food product. The present invention also provides use of potassium alginate for the manufacture of a postprandial GIP secretion inhibitor. The present invention also provides a method for inhibiting postprandial GIP secretion, which comprises administering potassium alginate to a subject in need thereof or causing a subject in need thereof to consume potassium alginate.Type: ApplicationFiled: November 28, 2008Publication date: June 4, 2009Applicant: KAO CORPORATIONInventors: Junko SUZUKI, Akira SHIMOTOYODOME, Tomohisa ICHIBA
-
Publication number: 20090124691Abstract: The present invention provides an agent for inhibiting a postprandial increase in blood insulin level, wherein the agent containing a monoacylglycerol as an active ingredient. An agent of the invention for inhibiting a postprandial increase in blood insulin level contains a monoacylglycerol as an active ingredient.Type: ApplicationFiled: April 4, 2007Publication date: May 14, 2009Applicant: Kao CorporationInventors: Nanami Takeno, Akira Shimotoyodome, Shinichi Meguro